关键字:Anifrolumab;阿尼鲁单抗;CRF2-1, IFN-R-1;1326232-46-5; IFNAR1; 公司简介 武汉佰乐博生物(Biolab Reagents)由五位毕业于华中科技大学,华中农业大学,武汉大学等知名高校,且具有二十年工作经验的生命科学领域顶级研究者创立于2021年,凭借丰富的产品开发经验,利用全球领先的技术平台,引进和整合全球高品质的...
Anifrolumab (anti-IFNAR1)是一种 I 型干扰素 (IFN) 受体拮抗剂,是一种重组单克隆抗体。Anifrolumab 能阻断 I 型干扰素的活性,可用于系统性红斑狼疮 (SLE) 的研究。 查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/Ab170489.html ...
Anifrolumab在67.7 nM浓度作用20分钟,可持续降低IFNAR1表面表达,并消除STAT1磷酸化[1]。在1和10 μg/mL浓度下,该化合物抑制B细胞向浆细胞的分化,作用时间为6至7天[1]。 Anifrolumab抑制I型IFN诱导的ISRE信号传导,对IFN-α亚型的IC50值范围为0.004至0.3 nM,对IFN-β和IFN-ω分别为0.03 nM和0.07 nM[1...
Guo X, Higgs BW, Bay‐Jensen AC, et al. Suppression of T cell activation and collagen accumulation by an Anti‐IFNAR1 mAb, Anifrolumab, in adult patients with systemic sclerosis. The Journal of Investigative Dermatology. 2015;135(10):2402-9. doi: 10.1038/ jid.2015.188...
体外Anifrolumab(67.7?nM;20 分钟)诱导表面 IFNAR1 持续减少并消除 STAT1 磷酸化[2]。 Anifrolumab(1 和 10 μg/mL;6 或 7 天)抑制 B 细胞分化为浆细胞[2]。 Anifrolumab 抑制 I 型 IFN 诱导的 ISRE 信号传导,具有 IC 50IFN-α 亚型的范围从 0.004 到 0.3?nM,IFN-β 和 IFN-ω 的范围分...
Anifrolumab is an immunoglobulin gamma 1 kappa (IgG1κ) monoclonal antibody that selectively binds to subunit 1 of INFAR1.2,11 This binding inhibits type I IFN signaling, thereby blocking the biological activity of type I IFNs. Anifrolumab also induces the internalization of IFNAR1, thereby...
OP0165 Beneficial Effects of An Anti-Ifnar1 Monoclonal Antibody on Immune Cell Dysregulation and Complement System Abnormalities of Systemic Lupus Erythematosus: An Exploratory Analysis of Phase IIB Clinical Trial of Anifrolumab Author links open overlay panelX. Guo, L. Wang, G. Illei, P. ...
3.1.2 Anti-type I interferon receptor antibodies Another promising strategy is to target directly IFN receptors rather than IFNs. Anifrolumab, is a fully human IgG1κ monoclonal antibody directed against the subunit 1 of the type I interferon receptor (IFNAR1). Following a successful phase I...
BioXCell热销产品–InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) 产品描述: 这种非治疗性生物类似药抗体使用与治疗性抗体Anifrolumab(阿尼鲁单抗)具有相同的可变区,使其成为相关研究用途的理想选择。这种Anifrolumab生物类似药抗体与人IFNAR1(干扰素-α/β受体亚单位1)反应。IFNAR-1与IFNAR-2在几乎所有...
If a patient develops an infection, or is not responding to standard anti-infective therapy, monitor the patient closely and consider interrupting SAPHNELO therapy until the infection resolves. Hypersensitivity Reactions Including Anaphylaxis Serious hypersensitivity reactions (including anaphylaxis) have been ...